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Volume 60, Number 3 Farber et al 583to the aortic stent component may be necessary to enable
treatment of these patients.
Whereas the current Ventana device trial is on hold as
of this writing, our data suggest that future design efforts
should be targeted at improvement in the proximal sealing
region in an attempt to treat paravisceral aneurysms
because it appears to have a sufﬁcient incorporation of renal
vessel locations. Attempting to use OTS devices outside
their intended instructions for use would deﬁnitely increase
the eligibility of patients but in our opinion signiﬁcantly
increases the risk of device-related complications. Each of
the aforementioned OTS devices differ in the intended
proximal sealing regions. The p-Branch device is able to
treat paravisceral aortic disease that extends to the base of
the SMA by using a fenestration for the SMA and a scallop
for the celiac artery. The Ventana device, on the other
hand, needs a 15-mm infra-SMA neck length because of
the large scallop conﬁguration, limiting it to the treatment
of pararenal aneurysms.
There were some limitations of this study. There were a
limited number of patients who had OTS implants. Further
studies with increased sample size and longer follow-up are
needed to prove that these devices are safe. We evaluated
only complex aneurysms referred to our center. Types of
aneurysms referred may be different at other institutions
and may have changed the results of our analysis. The im-
plants were also done at an institution with vast experience
in performing complex fenestrated endovascular repair.
These results and the learning curve may be different in
less experienced hands.
CONCLUSIONS
Whereas OTS device strategies will reduce the waiting
times for patients with complex aortic aneurysmal disease,
a signiﬁcant number will still require either complex open
or endovascular custom-made devices until additional de-
vice designs become available. Early experience with OTS
devices does not demonstrate any signiﬁcant renal risks;
however, the treatment numbers are low and should be
interpreted with caution until larger conﬁrmatory studies
are published. Further studies comparing the outcomes of
these techniques are required to establish the best approach
to handle endovascular repair of complex aortic aneurysm.
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excellent presentation, and congratulations on a nice manuscript.
This study demonstrates the difﬁculties that device engineers
and surgeons alike will have with expanding endovascular repair
to the branched segments of the aorta, particularly with ﬁnding de-
vices that do not have to be customized to the patient’s individual
anatomy.
Because of the wide variation in aneurysm location and the
variability of the visceral vessel anatomy, Dr Farber has demon-
strated that the current conﬁgurations of off-the-shelf (OTS)devices are unable to treat the majority of patients for whom
they were designed. He has also demonstrated that when these de-
vices do accommodate the patient’s anatomy within their intended
conﬁguration, they do a nice job of providing an adequate repair in
early follow-up.
Mark, I have two questions for you:
1. Where are these OTS devices going to go in the future? With
the current technology used in these devices, do you think we
will ever be able to reach the device companies’ goal of treat-
ing 60% to 70% of patients?
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aorta, we are obviously worried about whether you can suc-
cessfully complete the repair with regard to the visceral and
renal anatomy, but what is your philosophy about what consti-
tutes good aorta for a landing zone proximally? For example,
with juxtarenal and suprarenal aneurysms, why not always use
the distal thoracic aorta as a landing zone to ensure that you
are providing a good zone of seal and ﬁxation? Is there any
downside to that?
DrMark A. Farber. Thanks, Adam. I think I will handle your
second question ﬁrst about the scallops. First a commentdnot all
scallops are the same. If you look at the Ventana device, it is a very
large, wide scallop. It is what most of us would probably refer to as
a double-wide scallop. It is on the order of 20+ mm in width and
very deep. The current custom ZFEN device is a very narrow
scallop of only 10 mm. We as well as others in the United States
have changed our practice about how we manage very small scal-
lops. They can be malaligned, needing a superior mesenteric artery
stent, which is not the case for double-wide scallops. So we have to
be careful about saying scallops are all the same. I think all of us
know that as you become more comfortable doing these proce-
dures moving up into the SMA and the celiac, it does not add sig-
niﬁcant risk. It does not add that much more time, and it is more
about selecting the right patient. If you take some of the early data
from the Cleveland Clinic, their failures were in patients who
already had some minor dilation of the aortic neck in the paravisc-
eral section at the SMA, and so we have used centerline ﬂow anal-
ysis to plan; and whenever any signiﬁcant change is seen, 10% or
posterior disease in the aorta, we move our sealing zone up into
the distal thoracic aorta to try to get away from that. The problem
is access to devices that accomplish this, and if people try to shoe-
horn a device in a problem area, it is going to be more prone to
fail. I am sure your institution and many referral institutions are
the same. We see failed infrarenal devices, and if you go back to
the original imaging, the device was put in an already diseased
infrarenal neck, and that goes on to dilate and fail. I think from
that standpoint and to where we are going in the future, it ties into
your ﬁrst question. We will move up, but we will move up whenthe devices are available, and doing a four-vessel fenestration,
thereby giving yourself a 3-cm landing zone above the celiac, means
that any future repair is going tobemuch easier because you can atta-
ch that into a tube graft.
Your last question, what is the FDA thinking? Well, I do not
really know what the FDA is thinking. To say that it will let us do
these OTS devices I think is a little stretch. They are done under
investigational device exemption protocols, and I think we do
have to look at outcomes. If we take OTS devices that have a lim-
itation where you can put the renals and the SMA and say “we are
going to cheat on that and maybe we will move it here” for an ur-
gent or emergent case and we cannot wait for a custom-designed
device to ﬁt the patient speciﬁcally, then we have to assess the risks.
If the risks are that the patient has one renal and the renal does not
ﬁt and that the patient is going to go into renal failure if the device
does not ﬁt, then I think that is a lot different from someone who
says “well, there is an accessory renal and we are going to lose part
of a kidney function, not the whole function, and we can deal with
that.” I think this is going to be up to the individuals about how to
use it. If we use the devices inappropriately, eventually it is going to
ultimately hurt us in the outcome. I think most of us believe that
custom devices are still going to play a role, and in our practice I
think it is probably going to be 50/50 custom devices vs OTS
devices, unless we can get more designs to ﬁt more people, then
that may increase to 70%. The original 70% estimate on applica-
bility was based only on devices that were ordered out of Tim
Resch’s group in Sweden for a custom device. So he already
took out the pararenal, the paravessels, and unusual cases. What
we tried to look at is what comes to our practice because our
goal is to send a message to the corporations that this is what
we need to treat more patients in an off-the-shelf fashion. We
have to look at the renals closely, of which the right renal artery
is the most problematic. It actually comes up very high, and for
the p-Branch device, that interferes with the SMA stent, and
then the Ventana device does not extend high enough into the
aorta because of that wide scallop. So the message will be different
per device as to what needs to be modiﬁed to treat more patients,
but that is really what we are after.
